Search results
Nov 2, 2023 · We have demonstrated LNP delivery of RNA Writers into primary human T cells with an RNA template encoding a CAR cassette can achieve >20% CAR+ T cells without detriments to cell viability or proliferative capacity and have demonstrated ability to mediate tumor cell killing in vitro.
Apr 6, 2020 · A new methodology termed selective organ targeting (SORT) was recently developed that enables controllable delivery of nucleic acids to target tissues.
Jun 21, 2024 · This review focuses on strategies for achieving organ-selective delivery of nucleic acid-based therapeutics using LNPs (Scheme 1). We introduce present research on specific in vivodelivery tactics for LNPs and highlight certain LNPs designed for organ-selective targeting.
This review provides an incisive overview of the latest developments in the field of Ab-LNP technology, with a special emphasis on pivotal design aspects such as antibody engineering, bioconjugation strategies, and advanced formulation techniques.
Nov 2, 2023 · Using our novel T-cell LNPs, we have demonstrated single-dose in vivo delivery of GFP mRNA in two humanized mouse models. In the spleen of humanized NSG mice (pre-engrafted with human HSCs 12-weeks prior to study), we achieved GFP expression in 24% of human CD3 + T cells.
Jane joined the Tessera team in 2021 and is currently Executive Director, Head of Delivery Technologies. Prior to joining Tessera, she was technical lead of the nanoparticle program at Verily Life Sciences, where she worked on a variety of delivery technologies including LNP barcoding and extrahepatic nanoparticle delivery.
Lipid nanoparticles (LNPs) have emerged as highly effective delivery systems for nucleic acid-based therapeutics. However, the broad clinical translation of LNP-based drugs is hampered by the lack of robust and scalable synthesis techniques that can consistently produce formulations from early development to clinical application.
